Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

NCT04496687 · tracked via the Priya Life Science Australia tracker
Sponsor
SCAD Alliance
Phase
Observational
Started
2019-03-08
Last updated
2026-05-06

Condition(s) studied

Spontaneous Coronary Artery Dissection

Study summary

The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry, is to serve as an internationally collaborative, multicenter registry coordinated by an experienced and centralized coordinating center in an effort to increase the pace of participant recruitment, and thereby increase statistical power of studies related to SCAD.

The ultimate goal of iSCAD Registry is to facilitate the development of best practices and clinical guidelines for preventing SCAD or its recurrence. This observational study will be prospective and retrospective in its recruitment and will collect clinical information to better understand the natural history and prognosis for SCAD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Participants with a new diagnosis of SCAD or a history of confirmed or suspected SCAD will be prospectively recruited from either: 1. Inpatient wards of the enrolling medical centers during the acute presentation of SCAD, or 2. Outpatient cardiovascular clinics of enrolling medical centers. Participants must be: * 18 years of age or older * Diagnosis of SCAD or history of SCAD based on coronary angiography, either catheter-based or coronary CTA * Suspected SCAD by coronary angiography Exclusion Criteria: 1. Coronary dissection in association with atherosclerosis or as a result of iatrogenic injury 2. Inability to provide informed consent 3. Inability to complete study-related patient questionnaires 4. Inability to understand and complete patient questionnaires independently

Primary outcome measure(s)

  • Descriptive Data — Continuous time frame following index event for an average of 3 years from study contact date
    Participant demographic, historical, clinical characteristics, and treatment data
  • Clinical Outcomes — Continuous time frame following index event for an average of 3 years from study contact date
    Prospectively collected long-term outcomes including recurrent myocardial infarction, hospitalization, heart failure, stroke or transient ischemic attack, arrhythmia, and all cause mortality
  • Psychosocial Outcomes — Continuous time frame following index event for an average of 3 years from study contact date
    Prospectively collected data on participant's mental health using validated questionnaires

Trial sites (31)

FacilityCityRegionStatus
Cedars Sinai Los Angeles California
UCLA (University of California, Los Angeles) Los Angeles California
Kaiser Permanente Northern California San Francisco California
University of Colorado Aurora Colorado
Hartford Hospital Hartford Connecticut
University of South Florida Tampa Florida
Emory Healthcare System Atlanta Georgia
Northwestern Medicine Chicago Illinois
University of Kentucky Lexington Kentucky
Johns Hopkins Baltimore Maryland
Massachusetts General Hospital Boston Massachusetts
St. Luke's Mid America Kansas City Missouri
Washington University St Louis Missouri
Dartmouth-Hitchcock Lebanon New Hampshire
Catholic Medical Center Manchester New Hampshire
Mount Sinai New York New York
Columbia University Medical Center New York New York
Atrium Health Sanger Heart and Vascular Institute Charlotte North Carolina
University Hospitals--Case Western Cleveland Ohio
Oklahoma Heart Oklahoma City Oklahoma
Providence Portland Oregon
University of Pennsylvania Philadelphia Pennsylvania
Allegheny General Hospital, Allegheny Health Network Pittsburgh Pennsylvania
University of Pittsburgh Medical Center Pittsburgh Pennsylvania
Vanderbilt University Medical Center Nashville Tennessee
UT Southwestern Dallas Texas
Intermountain Murray Utah
University of Virginia Charlottesville Virginia
Inova Heart & Vascular Institute Fairfax Virginia
University of Washington Medicine Seattle Washington
Victor Chang Cardiac Research Institute Darlinghurst New South Wales
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04496687 on ClinicalTrials.gov ↗ ← All trials in Australia